skip to Main Content

Modest Gains in Metastatic Pancreatic Cancer Leave Room for Improvement

Modest Gains in Metastatic Pancreatic Cancer Leave Room for Improvement
Although a number of treatment options are available to patients with metastatic pancreatic cancer, regardless of whether they received FOLFIRINOX or the combination of gemcitabine and nab-paclitaxel (Abraxane) in the frontline setting, more data and more effective treatment regimens are needed to truly move the needle forward, explained Jordan D. Berlin, MD.

“Treatments for patients with pancreatic cancer have gotten better,” said Berlin. “We really have 2 to 3 lines [of treatment] depending on how you spread out the drugs. However, we need more [active] regimens.” Read more . . . 


Back To Top